Production

CordenPharma Colorado is partnering with BioMed Realty to expand its peptide development capabilities in Boulder with the lease of a 64,000-sf facility in Flatiron Park. Located near the CDMO’s large-scale peptide manufacturing hub, the state-of-the-art building will accommodate process development and analytical services, enabling seamless integration of advanced peptide API (Active Pharmaceutical Ingredient) creation from production to commercialization.

AbbVie is planning a $380 million expansion of its headquarters campus in North Chicago, Ill. Construction will begin in spring of 2026 on two plants for the production of active pharmaceutical ingredients (APIs). Enabling the creation of innovative treatments for neurological conditions and obesity, the next-generation facilities will integrate advanced manufacturing technologies with artificial intelligence (AI) to maximize purity, efficacy, and operational efficiency. Full production is expected to commence in 2029.

Johnson & Johnson is investing over $1 billion to create a next-generation cell therapy manufacturing facility in Lower Gwynedd Township, Pa. The state-of-the-art hub is part of a $55 billion commitment to expand the company’s infrastructure and capacity in the United States by early 2029, and supports plans to produce the vast majority of J&J’s innovative medicines domestically to meet the needs of U.S. patients.

Genentech, an independent subsidiary of Roche, is expanding the initial investment in its new biomanufacturing facility in Holly Springs, N.C., from $700 million to approximately $2 billion. Originally envisioned as a 700,000-sf complex, the project will now deliver increased production volume and scale capacity, significantly enhancing the company's U.S. supply chain.

Designing and building labs in the unlikely and constrained location of the prestigious Pacific Design Center (PDC) with Hollywood as a backdrop is a daunting task, requiring adherence to quality expectations, facilities management guidelines in a non-research environment, separation from existing high-end tenants, and compliance with infrastructure requirements. Cedars-Sinai, one of the largest nonprofit medical centers in the U.S., accepted the challenge after deciding to expand its research portfolio. Growing beyond its limited campus is necessary to accommodate the rapid growth of its research facilities and to aid in recruiting top scientists by providing innovative facilities with optimum resources. Hospital officials looked a half mile from their campus to the PDC, a designated cultural resource building complex designed by Cesar Pelli in the 1970s. Known in the 1980s and 1990s as a vibrant hub of premier art, design, and architectural showrooms, many of the tenants now have online shops rather than physical space in the cluster of buildings, leaving vacancies available for lease and an opportunity for Cedars-Sinai’s growth.

AstraZeneca opened a $300 million cell therapy facility in May of 2025 in Rockville, Md. Developed by Alexandria Real Estate Equites, the 84,264-rsf building features specialized environments for the production of chimeric antigen receptor therapies (CAR-T) and T-cell receptor therapies (TCR-T). Next-generation biomanufacturing suites will leverage advanced process controls to create life-saving personalized medicine treatments, spanning every step from culturing and formulation to testing.

The U.S. Department of Energy is constructing the Stable Isotope Production and Research Center (SIPRC) on the main campus of Oak Ridge National Laboratory in Tennessee. Designed by Gresham Smith, the $325 million facility will address a critical need for stable isotopes in medicine, science, industry, and security. SIPRC will be the nation’s first domestic production facility for enriched stable isotopes since 1998 and will reduce current dependence on diminishing reserves and foreign suppliers.